Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23733143 | 0.89 | LMNA (0.34) | KDM4EALDH1A1MEN1HPGDBLM | |
| SCHEMBL23733081 | 0.78 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL23733068 | 0.77 | ALDH1A1 (0.35) | KDM4EALDH1A1MEN1HPGDBLM | |
| SCHEMBL23733087 | 0.75 | — | — | |
| SCHEMBL23733083 | 0.73 | PLA2G7 (0.38) | KDM4EALDH1A1SMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL8609384 | 0.69 | ALDH1A1 (0.40) | KDM4EALDH1A1MEN1HPGDBLM | |
| SCHEMBL23732682 | 0.68 | SMN1; SMN2 (0.30) | KMT2ASMN1; SMN2 | |
| SCHEMBL16091679 | 0.64 | LMNA (0.37) | KDM4EALDH1A1MEN1HPGDBLM | |
| SCHEMBL23732645 | 0.62 | PTPN1 (0.36) | ALDH1A1L3MBTL1 | |
| SCHEMBL23732659 | 0.61 | LMNA (0.34) | KDM4EALDH1A1MEN1HPGDBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238155-A1 | CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL DISORDERS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238155-A1 | CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL DISORDERS | PYGL, HMOX2, MB | KDM4E 2143/4885ALDH1A1 976/4885MEN1 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.